Recent performance snapshot for CNO Financial Group (CNO)

CNO Financial Group (CNO) has attracted fresh attention after a recent share price move, with the stock closing at US$46.88 and showing mixed short term returns alongside longer period total returns.

That latest pullback sits against a stronger backdrop, with the 30 day share price return of 7.45% and year to date share price return of 11.09% alongside a 1 year total shareholder return of 21.57%, suggesting momentum has been building rather than fading.

If CNO's recent move has you thinking about where else capital could work hard, it may be a good moment to widen your search with 19 top founder-led companies

With CNO trading near its recent close of US$46.88, an intrinsic value estimate that is about 30% higher suggests a possible discount. However, given its solid past total returns, it is worth considering whether there is still a buying opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 1.3% Undervalued

CNO Financial Group's most followed narrative points to a fair value of $47.50, sitting just above the recent close at $46.88 and framing the current pricing as slightly below that estimate.

Accelerating growth in annuity and life/health policy sales, particularly driven by a rapidly aging U.S. population (11,000 Americans turning 65 each day) and increased focus on retirement income solutions, is expanding CNO's addressable market and supporting consistent, repeatable revenue gains. Strong momentum in digital and web-based direct-to-consumer channels, evidenced by 39% year-over-year growth and over 30% of D2C leads now from digital sources, is reducing customer acquisition costs and is expected to drive further margin expansion and scalability.

Curious what sits behind that fair value number? The narrative focuses on earnings power, margin expansion and a different future profit multiple than today. Want the full picture of how those pieces fit together?

Result: Fair Value of $47.50 (UNDERVALUED)

However, you also need to weigh risks such as prolonged low interest rates pressuring investment income and long term care claims shifting back toward higher pre pandemic levels.

Another View: What P/E Says About CNO

CNO might look attractive against a fair value estimate that sits about 29.5% above the current US$46.88 share price, but the P/E story is quite different. At 17.8x earnings, the stock is priced higher than the US Insurance industry at 11.3x and peers at 9.7x, and also above its own fair ratio of 15.1x. This points to valuation risk rather than a clear discount. So how much weight do you want to give a discounted cash flow style fair value when the earnings multiple is already stretched?

Next Steps

Mixed messages on value and risk so far? Take a closer look at the numbers, weigh the concerns against the potential upsides, and review the 3 key rewards and 2 important warning signs

Looking for more investment ideas?

If CNO has sharpened your focus, do not stop here. Use curated stock ideas to quickly spot other opportunities that could suit your portfolio.

• Target stability and income by reviewing companies that screen as potential 12 dividend fortresses with a focus on higher yields.
• Hunt for mispriced opportunities using the screener containing 21 high quality undiscovered gems that highlight quality businesses the market may be overlooking.
• Aim for resilience in tougher markets by scanning 66 resilient stocks with low risk scores for stocks that rate well on lower risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.